Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specific Use-results Study of IMJUDO Intravenous Infusion 25mg / IMFINZI Intravenous Infusion 120mg,500mg All Patient Investigation in Patients With Unresectable Advanced or Recurrent Non-small Cell Lung Cancer

NCT05826366 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05826366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specific Use-results Study of IMJUDO Intravenous Infusion 25mg / IMFINZI Intravenous Infusion 120mg,500mg All Patient Investigation in Patients With Unresectable Advanced or Recurrent Non-small Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 2, 2023
Completion date
April 30, 2025
Enrollment
296 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung